This morning Slovenia-based startup AmblyoPlay released its new digital vision therapy platform aimed at helping individuals with amblyopia, commonly called “lazy eye.” The subscription-based ...

Luminopia, Inc., a digital health company pioneering a new class of treatments for neuro-visual disorders, announced its first international licensing agreement with ROHTO Pharmaceutical Co., LTD, a ...

A new decision support tool can assist optometrists and ophthalmologists in the care of children aged 3 to 17 years with ...

A digital therapeutic (DTx) for amblyopia – sometimes known as lazy eye – has been shown to improve vision correction over standard therapy in a phase 3 trial, according to its developer Luminopia.

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

Crunchyroll, the global brand fueling anime fandom, is now part of an FDA-approved and doctor-prescribed VR treatment for kids with lazy eye. Through a new collaboration with digital health company ...

About 69% of pediatric patients had discontinued amblyopia therapy during COVID-19 even as their parents reported that adherence was good. Although parents reported good adherence to therapy, a new ...

Researchers are testing an unconventional way to treat amblyopia, better known as “lazy eye,” by briefly shutting the weaker eye down with anesthetic injections so the brain is forced to rewire. Early ...

Award-winning optometrist in Vancouver urges parents to recognize amblyopia symptoms early to protect children’s long-term visual development Amblyopia, commonly known as lazy eye, is one of the most ...

Please provide your email address to receive an email when new articles are posted on . NovaSight announced that it is launching CureSight, its digital therapy for amblyopia, to the U.S. market this ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted de novo premarket approval for Luminopia One, a digital therapy for children aged 4 to 7 ...